CELL REGULATORY SIALOPROTEIN

细胞调节唾液酸蛋白

• 批准号: 3493330
• 负责人: FLOYD E TAUB
• 金额: $ 5万
• 依托单位: SYNCHROCELL, INC.
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-03-01 至 1994-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3493330
• 关键词: antineoplastics; biomaterial development /preparation; cell differentiation; cell growth regulation; drug screening /evaluation; glycoproteins; growth inhibitors; sialate; tissue /cell culture

CeReS (Cell Regulatory Sialoprotein) is a molecule demonstrated to: 1. Inhibit primary, continuous and transformed cell lines, 2. Affect cells from species as diverse as insects and humans, 3. Cause one cell line to terminally differentiate, 4. Reversibly inhibit other lines (90%-98% of the cells recover), 5. Specifically arrest cells near the Gl/S interface, 6. Synchronously release cells to enter S phase and then mitosis (synchronization remains through at least one additional cell cycle). CeReS is distinct from all known drugs and cell surface components functionally and according to the limited peptide sequence and preliminary DNA sequence data available. The aims of this study are to determine the feasibility of using CeReS to improve and increase efficiency of cell culture, to provide new models for differentiation; and to test a wide variety of cancer cell lines for sensitivity or resistance to CeReS. Preliminary data indicates differential sensitivity of cells suggesting potential therapeutic uses. SynchroCell, the exclusive licensee of CeReS, believes this and related molecules will be important products for the research community, significantly aiding in understanding regulation and carcinogenesis and as a cell culture tool of commercial importance. Improved cancer therapies are potential applications of CeReS and of the knowledge gained with the aid of CeReS.

CeReS（细胞调节唾液酸蛋白）是一种分子，被证明：1。 抑制原代、连续和转化细胞系，2.影响细胞 从昆虫和人类等不同的物种，3。导致一个细胞系 最终分化，4。可逆地抑制其他线路（90%-98%的 细胞恢复），5.特别是在G1/S界面附近的细胞， 6. 同步释放细胞进入S期，然后进行有丝分裂 （同步化保持通过至少一个额外的细胞周期）。 CeReS不同于所有已知的药物和细胞表面成分 功能上和根据有限的肽序列， 初步DNA序列数据可用。 本研究的目的是确定使用CeReS进行 改善和提高细胞培养效率，提供新的模型 分化;并测试各种癌细胞系， 对CeReS的敏感性或抗性。 初步数据表明 细胞的不同敏感性提示潜在的治疗用途。 CeReS的独家授权商SynchroCell认为， 分子将是研究界的重要产品， 显著有助于理解调节和致癌作用， 作为具有商业重要性的细胞培养工具。 改进的癌症 治疗是CeReS和所获得的知识的潜在应用 在CeReS的帮助下